Children are our most important national resource. Children's brain, development, and behavior are important to their health, to their ability to contribute to society throughout life, and to the well-being of future generations. Children cannot make choices about their environment; it is up to adults to make the right decisions to ensure that they are protected. Scientists have a significant role to play in assuring that these protections are provided to our children by identifying preventable causes of developmental disabilities and impairment. Federally funded research has played a critical role in identification of long-term effects on the developing brain of exposures to lead, methyl mercury, and polychlorinated biphenyls (PCBs) . It is critical that such research be clearly translated into policy.
We know that infants and children may be more susceptible than adults to some chemicals (1) , and their exposures to chemicals in foods and in the environment are different, and often greater, than those for adults. Proportionate to body weight, children eat more of certain types of foods, drink more fluids, and breathe more air than adults (2) . Toddlers crawl on the floor and grass outside; the older children spend a lot of time outdoors. Thus, children are often more exposed to potentially harmful pollutants.
A research agenda for public health is driven by a number of factors that operate simultaneously including scientific advances, public policy concerns, and public health value. As we come to the end of the National Institutes of Health-declared "decade of the brain," it is clear that the science of brain development is developing rapidly. There is good reason to expect that the research community is poised to make breakthroughs in our understanding of neurological development and its disruption by exposures to environmental agents. This article addresses some of the policy and public health issues that are relevant to an agenda for research in (2) . In fact, the committee believed that the U.S. EPA already applied that additional factor when it found significant prenatal developmental toxicity and urged the agency to also apply the factor when postnatal effects are found (2 This provision has been especially controversial, first, because industry opposed its enactment in the first place, second, because of disagreements among scientists about whether it should have been required, and third, because of difficulties in implementation, as discussed below.
Risk is a function of hazard and exposure. The basis of most pesticide health decisions is hazard information from animal tests. The most fundamental assumption in hazard identification is that if a chemical is hazardous to animals, it is assumed hazardous to humans. A related assumption is that animal testing predicts relative potency for humans. When the U.S. EPA developed the concept of the reference dose (RfD), it recognized that both interspecies differences and intraspecies variability need to be taken into account when using animal studies in assessing risks to humans (5 (6) .
Generally, for noncancer effects, risk is characterized as a percent of the RfD. The chronic RfD is an estimate of a daily exposure to a population, which, over a 70-year life span, is likely to have no significant deleterious effects (5) . The acute RfD is its equivalent for short-term exposure. To calculate an RfD, the risk assessor first chooses the most appropriate-usually the most sensitiveeffect from a chronic or acute study. Next, the no-observable adverse effect level (NOAEL) is identified for this effect. Finally, the assessor identifies uncertainties in the data and applies uncertainty factors to the NOAEL-generally a 10x factor to account for uncertainty in extrapolating from animals to humans and a 1 Ox factor to account for the variation within the human population. At the U.S. EPA, modifying factors between 3-and 10-fold are applied when critical studies are missing.
Although application of these factors is fundamental to risk assessment as we know it today, few are aware of their origins. These factors were not directly derived solely from scientific experiments. Rather the FDA based them on evaluation of a modest database, along with a large portion of scientific judgment that supported the view that initially one factor of 100 would cover all sources of variability. Over time, this 100-fold factor was split into two factors of 10 (6).
Applying the additional FQPA 10x factor to protect children has become one of law's most challenging policy issues. While the U.S. EPA applied modifying factors when prenatal developmental studies were incomplete, there was not a routine application of an additional 1Ox factor when significant prenatal effects were observed. Further, Congress directed the U.S. EPA to account for uncertainties in exposure as well as hazard. This was a new procedure with no precedent for the U.S. EPA to use for its application. Since enactment of the FQPA, the U.S. EPA has issued successive draft policies describing criteria for removal of this uncertainty factor.
An important policy question that has emerged from the debate about the FQPA 10x factor is whether current toxicity testing requirements and exposure information are adequate to assure the safety of infants and children, or whether the U.S. EPA should routinely require additional information. One question that has emerged that needed to be answered quickly is whether the developmental neurotoxicity test (7) (11) .
This lack of toxicity data compromises the public's right to know about chemicals in their homes, their workplaces, and the products they buy. In April 1998, Vice President Gore issued a challenge to industry to come forward with complete basic test data for these HPV chemicals. In September 1998, the Chemical Manufacturers Association, Environmental Defense, and the U.S. EPA announced a voluntary initiative to fill these information gaps. (12) .
The vice president also directed the U.S. EPA to establish testing requirements for chemicals to which children may be exposed. This effort will examine several dozen chemicals to which children are likely to be exposed and ensure that they receive testing for potential hazards to children. The required testing will be extensive-comparable to that required for pesticides. At Autism Autism, once believed to be a rare disorder, is a complex developmental disorder with onset and diagnosis during the first three years of life. Autism is part of a collection of disorders referred to as pervasive development disorder or autism spectrum disorder. These disorders involve deficits in social interaction, communication, behavior, and imagination (16) . Some people with autism may function below normal intellectual levels, while others may do well in school but have severe social impairments. Some never speak. Success in some cases seems to be best with early education and intervention. Autism may be associated with specific structural brain abnormalities. An estimated 135,000 United States children ages 3-21 have been diagnosed with autism and autism spectrum disorders. The prevalence is estimated at 1-2 per 1,000 children under age 15 (17) (18) (19) (20) . The rate of autism is believed to be increasing both nationwide and worldwide. Older research estimated the prevalence of autism to be only 0.4-0.5 per 1,000 children. Data from Europe are more extensive, but in the United States, the only effort to monitor prevalence of and trends in autism is the CDC system in metropolitan Atlanta, Georgia. Although research indicates that autism may involve interactions between genetic susceptibility and environmental exposures, there have been few efforts to link autism cases with environmental exposure levels.
Because we have so little information about autism, it is difficult to assess the costs to society. However, the CDC estimated that, in 1995 alone, the total costs for special education for autistic children in the United States were more than $160 million (16) . In addition, 1 child with autism can require residential care costing between $70,000 and $100,000 per year (21) . Families bear a tremendous burden of the costs; they must adjust in numerous ways, sometimes at the cost of a parent's career, to care for the autistic child. In addition to these costs there is an unknown but certainly significant burden and cost to society for those children who are not given adequate education when they are young, and those with forms of autism that have long-term impacts on their functioning in society.
In California, the number of children with autism enrolled in statewide Department of Developmental Services programs rose from 3,864 in 1987 to 11,995 in 1998, an increase of more than 210% during those 11 years. By comparison, enrollment of children with other disorders such as cerebral palsy and epilepsy increased by only 30-45% for the same period (22) . The rising number of children diagnosed with autism may reflect an actual increase or be due in part to changes in diagnosis and reporting, specifically greater recognition of a broader and subtler set of symptoms associated with the disorder. For instance, autism spectrum disorders include not only autism but also Asperger's syndrome, childhood disintegrative disorder, Rett's syndrome, and pervasive developmental disorders. The changes in criteria for diagnosis of autism complicate efforts to understand trends of prevalence over time.
The cause or causes of autism are not yet known. A strong hereditary component was discovered through early studies of twins (23) . There is evidence for interaction with environmental factors such as pre-or postnatal exposure to infectious diseases and exposure to the drugs valproic acid and thalidomide (24) . Autism is known to be associated with birth defects. Thalidomide when taken by a pregnant woman between days 20 and 24 of gestation not only causes a high rate of missing or shortened limbs (phocomelia) but also has been associated with a high rate of autism (25) . This is the time of the closure of the neural tube in fetal development, suggesting that there could be an embryological origin to autism. Further, a large percentage of children with autism have minor malformations of the ear, which would occur in the same time period, compared with children with and without other developmental disorders (26) .
Autopsy studies of humans and animal models suggest that there is a very specific set of brain anomalies associated with autism (absence of the facial nucleus and superior olive along with shortening of one region of the brain stem). These studies indicate that these changes can be caused by either a genetic abnormality (lack of the HoxA 1 gene in mice) or exposure to an agent such as thalidomide or valproic acid just after neural tube closure during fetal development (27) (30) . The risk of cerebral palsy is strongly associated with birthweight and preterm birth-the smaller the infant and the younger the gestational age, the greater the risk. Approximately one in every 20 very low birth weight babies who survive infancy will develop disabling CP, compared to 1 in 1,000 of all normal birth weight infants.
CP is one of the most costly developmental disorders affecting children, adding an estimated $500,000 in lifetime medical costs for each affected child (31) . One in every 500 children in the United States lives with some form of CP today (32) (33) (34) (35) (36) . The prevalence of cerebral palsy is believed to be remaining constant or increasing slightly, possibly because more very low birth weight infants are surviving as treatment improves; many of these infants will suffer subsequent developmental disabilities. Although very low birth weight infants (< 1,500 g) are 100 times more likely to develop disabling CP than infants of the most common weight groups (37), the higher number of normal birth weight babies results in their contributing to more than half of all CP cases (38) . Besides low birth weight and preterm birth, other risk factors include being born feet first, maternal bleeding, and certain other adverse clinical signs in the newborn period (39) .
Mentl Retardtion
Mental retardation (MR) is a varied group of conditions characterized by cognitive limitations due to organic brain dysfunction, with onset no later than 18-22 years of age (40) . The definition of MR also is based on functional limitations in areas that include daily living skills, social skills, and communication. About 50% of children with MR also have structural birth defects. In the 1995-1996 school year, approximately 600,000 U.S. school children age [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] with MR were served in special education programs as required by law. Costs were $3.3 billion to the federal government and much more for state and local governments (41) . The average cost of caring for children with more serious MR is difficult to estimate, but it may be as high as 10 times the cost of providing for a child without a disability.
The cause of most cases of MR among children is unknown. Some environmental factors include fetal alcohol syndrome, heavy metals poisoning such as lead and methyl mercury, and infections such as meningitis. Environmental exposure to lead can cause a general reduction in IQ and, at high enough doses, mental retardation. MR also occurs in association with a number of major birth defects, CP, very preterm birth, and very low birth weight. Therefore, as with CP, identifying causes of MR is critical. Since 1991, the CDC has tracked MR in metropolitan Atlanta. According to the CDC, the prevalence of MR in 3-to 10-year-old children between 1991 and 1994 was 9.7 per 1,000 children, or about 1%.
We know very little about fundamental issues related to the health and neurological development of children, including prevalence and trends for some of the most serious developmental disabilities, autism, CP, and MR. We know even less about which environmental factors may be detrimental. We have little information about developmental toxicity and exposure of children to pesticides and even less information about industrial chemicals. The result is that we do not know how to prevent most childhood developmental and behavioral disorders.
Conclusions
What kind of research will be appropriate? A research agenda for children's neurodevelopment needs to be backed up by a strong national public health information and assessment function to understand the rates and patterns of developmental disabilities in our children. We do not have much information on exposures to children, yet opportunities exist. New findings in genetics and in mechanism-based toxicology research provide further opportunities to advance the field. A stronger linkage between public health surveillance and basic research efforts could help identify relationships between environmental exposures, as well as genetic components and gene-environment interactions, and major developmental disabilities.
Much of the recent early development research has focused on socioeconomic status as a measure of early childhood deprivation. Lower socioeconomic status communities and minority communities have disproportionate shares of many environmental exposures as well as nutritional and other disparities (42l. Collaboration between developmental and environmental researchers is needed to elucidate the role of environment as a component of early childhood deprivation. We need research that not only addresses the most severe impacts but also examines the relationship between population exposures to neurotoxicants and the full continuum of intellectual, performance, and behavioral measures. The cases of lead, PCBs, and methyl mercury hold lessons that small individual impacts, over an entire population, can exact enormous costs to society.
An environmental prospective study may be the best avenue to fully address several of these concerns. Prospective studies were necessary for the identification of the subtle longterm neurodevelopmental impacts of lead and PCBs to be identified. Prospective data collection, beginning prenatally, could include a broad range of environmental exposures. Tools are available for assessing many important risk factors, including genetic susceptibility, biomarkers of environmental exposures, and hormonal status. Long-range follow-up of children would be used to assess neurodevelopment outcomes over time.
With the large number of poorly assessed chemicals used in commerce known to be or possibly harmful to development, such research will be vital to ensure adequate protection for children. If the 1990s was the decade of the brain, perhaps the next decade can be dedicated to using our newfound knowledge on how the brain develops and functions to identify and prevent causes of developmental disabilities.
